178 related articles for article (PubMed ID: 11029515)
1. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
Matthey B; Engert A; Barth S
Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
[TBL] [Abstract][Full Text] [Related]
2. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
3. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
4. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
[TBL] [Abstract][Full Text] [Related]
5. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
Nagata S; Onda M; Numata Y; Santora K; Beers R; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Jul; 8(7):2345-55. PubMed ID: 12114439
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
[TBL] [Abstract][Full Text] [Related]
8. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
[TBL] [Abstract][Full Text] [Related]
9. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
10. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
Matthey B; Engert A; Klimka A; Diehl V; Barth S
Gene; 1999 Mar; 229(1-2):145-53. PubMed ID: 10095114
[TBL] [Abstract][Full Text] [Related]
11. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
12. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.
Tur MK; Sasse S; Stöcker M; Djabelkhir K; Huhn M; Matthey B; Gottstein C; Pfitzner T; Engert A; Barth S
Int J Mol Med; 2001 Nov; 8(5):579-84. PubMed ID: 11605031
[TBL] [Abstract][Full Text] [Related]
13. Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.
Rozemuller H; Chowdhury PS; Pastan I; Kreitman RJ
Int J Cancer; 2001 Jun; 92(6):861-70. PubMed ID: 11351308
[TBL] [Abstract][Full Text] [Related]
14. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
[TBL] [Abstract][Full Text] [Related]
15. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld JC; Tesch H; Bohlen H; Diehl V; Engert A
Cytokines Mol Ther; 1996 Sep; 2(3):139-46. PubMed ID: 9384698
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
[TBL] [Abstract][Full Text] [Related]
17. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
[TBL] [Abstract][Full Text] [Related]
18. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
[TBL] [Abstract][Full Text] [Related]
19. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
Brinkmann U; Lee BK; Pastan I
J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
[TBL] [Abstract][Full Text] [Related]
20. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
